NCT00130156已完成4 期
Effects of Combination Therapy With an α1-blocker (Sustained-release Preparation of Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in the Treatment of Patients With Mild to Moderate Essential Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Eisai Inc.
- 入组人数
- 93
- 试验地点
- 1
- 主要终点
- Blood Pressure
研究概览
简要总结
The purpose of this study is to investigate the efficacy and safety of Bunazosin with Valsartin compared to Doxazosin with Valsartin for patients with mild to moderate essential hypertension accompanied by metabolic syndrome.
详细描述
This clinical study will comprise a 1 to 2-week washout period, a 5-week mono therapy period with AngiotensinⅡantagonist, and an 8-week alpha blocker add-on treatment period. Total study period will be 15 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with mild to moderate essential hypertension, with the following criteria:
- •Washout period (Week -2)
- •Male or female subjects aged 20 to 80 years
- •Systolic blood pressure (SBP):140 mm Hg but <180 mm Hg and/or diastolic blood pressure (DBP):90 mm Hg but <110 mm Hg
- •Subjects who have given written informed consent prior to participation in the trial and who undertake to comply with the protocol
- •Angiotensin II antagonist mono-therapy period (week 0)
- •Subjects with systolic blood pressure >= 140 mm Hg but <180 mm Hg and/or diastolic blood pressure >= 90 mm Hg but <110 mm Hg
- •Presence of any 2 of the following 4 risk factors
- •Waist circumference: male > 90 cm, female > 80 cm
- •Triglycerides >= 150 mg/dl
- •HDL cholesterol: male < 40 mg/dl, female < 50 mg/dl
- •Fasting glucose >= 110 mg/dl
- •Angiotensin II antagonist with add-on Bunazosin or Doxazosin treatment period (Week 5)
- •SBP >=140 mm Hg or decrease < 10 % OR
- •DBP >=90 mm Hg or decrease < 10 % comparing the blood pressure at the entry of the Angiotensin II antagonist mono-therapy period.
排除标准
- •Subjects with the following conditions are not eligible for participation：
- •a) Washout period (Week -1 or -2)
- •Subjects with severe hypertension (SBP>=180 mm Hg or DBP>=110 mm Hg).
- •Subjects who have proven or suspected hypersensitivity to quinazoline derivatives
- •Subjects who have a history of alcohol or drug abuse.
- •Subjects with past or present evidence of cancer
- •Subjects who have a past history of arterial fibrillation, heart failure (LVEF<40%), acute coronary syndrome, myocardial infarction, stroke or severe arrhythmia.
- •Subjects who are severely obese (BMI>30 kg/m2)
- •Women who are pregnant or lactating or suspected of being pregnant.
- •Subjects who have previously participated in any clinical trial of new or unapproved substances within the 12 weeks before starting of washout period
- •Subjects on other anti-hypertensive or lipid-lowering medication
- •Inability to return for scheduled visits or comply with any other aspect of the Protocol
- •Subjects with poorly controlled diabetes mellitus (HbA1c > 10%)
- •Subjects with concurrent serious hepatic or renal disorders (defined as AST and/or ALT > 3 times upper normal limit or Cr > 2mg/dl).
- •Subjects who, in the opinion of the investigators, are poor medical candidates or pose any other risk for therapy with an investigational drug.
研究组 & 干预措施
2
Experimental
干预措施: Doxazosin (Drug)
2
Experimental
干预措施: Valsartin (Drug)
1
Experimental
干预措施: Bunazosin (Drug)
1
Experimental
干预措施: Valsartin (Drug)
结局指标
主要结局
Blood Pressure
时间窗: Week 0, Week 4, Week 9, Week 13.
次要结局
- Safety and tolerability.(Week 4, Week 9, Week 13.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Treatment of Symptoms After Stent Placement for Urinary Tract ObstructionUreteral ObstructionNCT01741454University of Wisconsin, Madison181
已完成
2 期
Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic MelanomaMetastatic MelanomaNCT00308607University of Turku27
已完成
1 期
A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung CancerLung CancerNCT00238628Stanford University6
招募中
不适用
Effect of on combination therapy with irbesartan and amlodipine besilate on clinical blood pressure, home blood pressure and blood pressure variability in hypertensive patients with chronic kidney diseaseHypertension with chronic kidney disease (CKD G1-G4)JPRN-UMIN000013213Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine30
招募中
3 期
The effect of a combination of beta-blockers, angiotensin receptor blockers, and calcium channel blockers in aortic stenosisAortic stenosisCardiovascular - Other cardiovascular diseasesACTRN12621001732875niversity of Otago1,250